KALA BIO (KALA) risk factors

Item 1A of every KALA BIO, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open KALA in Gloom →

KALA BIO's chart, financials and news, free in your browser.Open KALA in Gloom →

FY2025 10-K risk factors
66 risks23 new25 dropped18 reworded
KALA BIO pivoted its business strategy toward AI-powered life sciences platforms, specifically licensing Researgency and shifting away from clinical biologics development.
Filed Apr 15, 2026
FY2024 10-K risk factors
68 risks
KALA BIO depends heavily on developing its lead biologic candidate, KPI-012, while facing recurring operating losses, substantial funding requirements, and reliance on third-party manufacturers.
Filed Mar 31, 2025